An individualised risk-adapted protocol of pre-and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial
A Grigg, B Butcher, B Khodr, A Bajel, M Hertzberg, S Patil, AB D'Souza, P Ganly, P Ebeling, E Wong
BONE MARROW TRANSPLANTATION | NATURE PUBLISHING GROUP | Published : 2017
Bone loss occurs frequently following allogeneic haematopoietic stem cell transplantation (alloSCT). The Australasian Leukaemia and Lymphoma Group conducted a prospective phase II study of pretransplant zoledronic acid (ZA) and individualised post-transplant ZA to prevent bone loss in alloSCT recipients. Patients received ZA 4 mg before conditioning. Administration of post-transplant ZA from days 100 to 365 post alloSCT was determined by a risk-adapted algorithm based on serial bone density assessments and glucocorticoid exposure. Of 82 patients enrolled, 70 were alive and without relapse at day 100. A single pretransplant dose of ZA prevented femoral neck bone loss at day 100 compared with ..View full abstract
This study was supported with funding and the provision of zoledronic acid by Novartis Pharmaceuticals Australia Pty Ltd.